The company is running both pivotal trials and a sales team.
The trials, if successful, will extend the label significantly to folfirinox and to interventional radiology. The company is funding these and they will run until Feb-May next year.. The GBA trial is also a pivotal trial but will be funded, which means cashflow as well as news flow probably for a couple of years.
If the company wasn't selling at the same time, the cash burn would be much less and the results of these trials would add significant value.
Running a sales team at the same time is a financial burden, especially when getting each new hospital onboarded is complex and has startup costs. Once onboarded, the roi should flow.
All the while someone is playing games on the market.
I think that just a sniff of corporate interest is required here. A partnership, a research collaboration, whatever it is. Just a signal that a bigger player is paying some attention, and maybe willing to take some of the funding heat off further capital needs.
OSL Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)